Europe Sexual Transmitted Infections (STI) Diagnostics Market: By Disease Type (Chlamydia and Gonorrhea, Trichomoniasis and Mycobacterium Genitalis, Syphilis, Vulvovaginal Candidiasis, Bacterial Vaginosis, Group B Streptococcus, and Herpes Simplex Virus), By Diagnostic Test Type (Cultural Test and PCR Test), By End User (Public and Private), and Country

Purchase Option

$ 3100
$ 4600
$ 6900

Europe Sexual Transmitted Infections (STI) Diagnostics Market size was valued at USD 306.2 million in 2023 and grew at 3.9 % CAGR over the historical years (2019 - 2023). The market is projected to reach USD 375.4 million by 2030 at a CAGR of 3.1%.  In Europe, the market is driven by some key factors which are rising STD rates, increased awareness, technological advancements, increased population with multiple casual sex partners, and government initiatives in addition to these, it is available for free tests, and the availability of test kits is driving the growth of the market. Across Europe, rates for STDs like Chlamydia, Gonorrhea, and others have been steadily increasing, particularly among young adults. This rise in infections is prompting a surge in demand for diagnostic tests.

Chlamydia and Gonorrhea are the most commonly screened diseases in the European region, followed by TV and MG. The total number of PCR and culture tests estimated volume in 2023 is 38.8 and 5.7 million respectively, in public and private labs in the Europe region approximately 60% of the rest are done in the public labs and 40% are done in private labs. In Europe, most laboratories rely on in-house laboratory-developed tests (LDTs) to diagnose STDs. However, new EU regulations will decrease the dependence on LDTs and promote the use of commercial kits for diagnosis, which could be seen as a potential opportunity for STD diagnostic kits. In terms of value. Multiplex testing, home testing kits, and digital health integration are opportunities in the STD diagnostics market.  Focus on point-of-care testing,  self-sampling techniques, automation, and high-throughput testing are the trends in the STD diagnostics market.  Stigma, reimbursement policies, and data privacy concerns are the constraints in the European region. By understanding these drivers, constraints, opportunities, and trends, stakeholders in the European STD diagnostics market can strategize for future growth and make a positive contribution to public health efforts in the region.

Europe STD Diagnostics Market Key Developments:
  • In June 2021, Bio-Rad Laboratories, Inc. and Seegene Inc. entered into a collaboration to produce molecular diagnostic products for infectious diseases. As part of this collaboration, Seegene began providing diagnostic tests that are compatible with Bio-Rad’s LFX960x Real-Time PCR System.
  • In December 2020, Stilla Technologies, a leading European provider of pioneering solutions for high-precision genetic analyses, launched a dedicated digital PCR MIX reagent line for optimal performance with Crystal Digital PCR.

Europe STD Diagnostics Market Dynamics

The rise in infections is prompting a surge in demand for diagnostic tests. Public health campaigns and educational initiatives are fostering greater awareness about STDs and the importance of early detection. This is encouraging individuals to seek testing, further propelling the market for STD diagnostics, the development of more sophisticated and user-friendly diagnostic tests, such as rapid point-of-care tests and home testing kits, is making STD testing more accessible and convenient. The rising population engaging in casual sexual encounters increases the demand for STD testing. As awareness grows about the importance of regular screening, individuals seek testing services more frequently. Many European governments are implementing programs to promote STD screening and diagnosis. This includes funding initiatives and streamlining access to testing services. The advent of multiplex tests that can simultaneously diagnose multiple STDs can enhance efficiency and encourage broader screening. The growing acceptance and use of home testing kits offer a convenient and discreet option for STD diagnosis, potentially reaching a wider population.

Europe STD Diagnostics Market Segmentation

By Disease Type
  • Chlamydia and Gonorrhea
  • Trichomoniasis and Mycobacterium Genitalis
  • Syphilis
  • Vulvovaginal Candidiasis
  • Bacterial Vaginosis
  • Group B Streptococcus
  • Herpes Simplex Virus
By Diagnostic Test Type
  • Cultural Test
  • PCR Test
By End User
  • Public
  • Private

Frequently Asked Questions

The STD diagnostics market was valued at USD 306.2 million in 2023 and grew at 3.9 % CAGR over the historical years (2019 - 2023). The STD Diagnostics Market is projected to reach USD 375.4 million by 2030 at a CAGR of 3.1 %.

• Rising STD Rates
• Increased Awareness
• Technological Advancements
• Increased Population With Multiple Casual Sex Partners
• Government Initiatives.

• Stigma
• Reimbursement Policies
• Data Privacy Concerns

• Focus On Point-of-Care Testing
• Self-Sampling Techniques
• Automation
• High-Throughput Testing

• Multiplex Testing
• Home Testing Kits
• Digital Health Integration

Market research is segmented based on disease type, diagnostic test type, end-users, and region.

Germany is the dominant region in Europe's STD Diagnostics Market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
  • Roche Holdings AG
  • Abbott Laboratories
  • Becton Dickinson and Company
  • Hologic Inc.
  • Danaher Corporation
  • Affymetrix
  • bioMerieux
  • Cepheid Inc.
  • Alere Inc.
  • DiaSorin
  • Orasure

Adjacent Markets